Abstract Details

Title Non-motor Symptoms (NMS) Improvement is Positively Correlated with Baseline NMS Burden and Improved Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-carbidopa Intestinal Gel: A Post-hoc Analysis from the GLORIA Registry

Topic Movement Disorders

Presentation(s) P1 - (-)

Poster/Presentation
Number 038

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
Werner Poewe, MD (University Hospital of Neurology) PRESENTER	Werner Poewe, MD has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Affiris . Werner Poewe, MD has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alterity, AbbVie, BIAL, Biogen, Britannia, Lilly, Lundbeck, Neuroderm, Neurocrine, Denali Pharmaceuticals, ,Roche, Takeda, UCB and Zambon . Werner Poewe, MD has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AbbVie, Britannia, BIAL, STADA, Lundbeck, Zambon. The institution of Werner Poewe, MD has received research support from MJFF; EU Horizon programme. Werner Poewe, MD has a non-compensated relationship as a Committee member with Movement Disorder Society that is relevant to AAN interests or activities.
Lars Bergmann	Lars Bergmann has received personal compensation for serving as an employee of Abbvie. Lars Bergmann has stock in Abbvie.
Angelo Antonini, MD	Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BIAL. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ABBVIE. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Antonini has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for THERAVANCE. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ABBVIE. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ZAMBON. Dr. Antonini has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BOEHRINGER.
Kallol R. Chaudhuri, MD, FRCP	Dr. Chaudhuri has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie, Acadia, GSK, Scion, Britannia , Lobsor. Dr. Chaudhuri has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie, Britannia, Scion, Sunovion, UCB, . Dr. Chaudhuri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie, Britannia, UCB, Zambon. Dr. Chaudhuri has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NPJ PD journal. The institution of Dr. Chaudhuri has received research support from Britania Pharmaceuticals, AbbVie, UCB, GKC, Bial, Aacdemic grants: EU, IMI EU, Horizon 2020, Parkinson's UK, NIHR, PDNMG, EU (Horizon 2020), Kirby Laing Foundation, NPF, MRC, Wellcome Trust.